On November 14, 2026, China published its 2026 national basic medical insurance list. According to The Paper’s report published that day, relmacabtagene autoleucel injection, sold as Benoda by JW Therapeutics, became the first and, at the time, only CAR-T therapy on the list.
The negotiated insurance-access price was not disclosed. Industry sources cited by The Paper estimated that it could fall below 300,000 yuan, with patients’ out-of-pocket costs after reimbursement potentially below 100,000 yuan. Those figures are estimates, not confirmed prices or guaranteed patient costs.
JW Therapeutics chairman and CEO Tian Feng told The Paper that negotiations involved repeated discussions about what patients could afford and what the company could sustain. He attributed the company’s room to reduce its price in part to greater control over its lentiviral-vector manufacturing technology, which he said reduced its reliance on costly overseas materials.
The product had entered China’s first national commercial-insurance innovative-drug list in 2025. Tian said that listing had not produced a large immediate increase in use: the company treated more than 200 patients a year, about one-third of whom had commercial-insurance support. He said it was too early to estimate how much demand would grow after entry into basic insurance, but that the company had production capacity in reserve.
The insurance listing concerns a costly, individually manufactured treatment for lymphoma. It does not establish the final amount any particular patient will pay.
Source: m.thepaper.cn (originally published 2026-11-14 16:53 UTC+8)



